Takeda Pharmaceutical Company Limited (TAK) |
|
16.43 0.03 (0.18%)
|
03-22 16:00 |
|
Open: |
16.36 |
Pre. Close: |
16.4 |
|
High:
|
16.58 |
Low:
|
16.41 |
|
Volume:
|
1,968,336 |
Market Cap:
|
51,279(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 3:51:48 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 19.36 One year: 22.61 |
| Support: |
Support1: 15.71 Support2: 15.18 |
| Resistance: |
Resistance1: 16.57 Resistance2: 19.36 |
| Pivot: |
15.99 |
| Moving Average: |
MA(5): 16.42 MA(20): 15.85
MA(100): 15.2 MA(250): 14.45 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 92.7 %D(3): 92.5  |
| RSI: |
RSI(14): 68.5 |
| 52-week: |
High: 16.57 Low: 12.27 |
| Average Vol(K): |
3-Month: 2,730 (K) 10-Days: 2,848 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TAK ] has closed below upper band by 13.8%. Bollinger Bands are 40.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
16.51 - 16.6 |
16.6 - 16.69 |
|
Low:
|
16 - 16.13 |
16.13 - 16.24 |
|
Close:
|
16.22 - 16.4 |
16.4 - 16.56 |
|
Company Description |
|
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. |
Headline News |
Tue, 21 Mar 2023
Dengue Fever Pipeline Assets Segmented by Stage, Product Type ... - Digital Journal
Tue, 21 Mar 2023
Price Growth & Yield: For That Magical Combo, Leave the U.S. - Nasdaq
Mon, 20 Mar 2023
AAD 2023: Takeda's TAK-297 hits endpoints in phase IIb psoriasis trial - BioWorld Online
Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On Martin Zweig - 3/19 ... - Nasdaq
Sat, 18 Mar 2023
Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold ... - MarketBeat
Sat, 18 Mar 2023
2023-03-18 | NYSE:TAK | Press Release | Takeda Pharmaceutical ... - Stockhouse
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
0 (M) |
| Shares Float |
3,120 (M) |
|
% Held by Insiders
|
3.07e+009 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
6,160 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0.66 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1 |
|
Profit Margin (%)
|
6.9 |
|
Operating Margin (%)
|
13.1 |
|
Return on Assets (ttm)
|
2.4 |
|
Return on Equity (ttm)
|
4.7 |
|
Qtrly Rev. Growth
|
21.7 |
|
Gross Profit (p.s.)
|
3.53 |
|
Sales Per Share
|
5.71 |
|
EBITDA (p.s.)
|
1.59 |
|
Qtrly Earnings Growth
|
106.8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
25.03 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
16.52 |
|
Price to Sales
|
2.89 |
|
Price to Cash Flow
|
0.01 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
5.03e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2009-12-14 |
|
Ex-Dividend Date
|
2021-09-28 |
|
Your Ad Here
|
|
